STRATA Skin Sciences, Inc. (SSKN)
NASDAQ: SSKN · Real-Time Price · USD
2.890
-0.080 (-2.69%)
Dec 20, 2024, 4:00 PM EST - Market closed

Company Description

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America.

The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.

The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions.

It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne.

The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016.

STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.

STRATA Skin Sciences, Inc.
STRATA Skin Sciences logo
Country United States
Founded 1989
IPO Date Oct 28, 2005
Industry Medical Devices
Sector Healthcare
Employees 99
CEO Dolev Rafaeli

Contact Details

Address:
5 Walnut Grove Drive, Suite 140
Horsham, Pennsylvania 19044
United States
Phone 215 619 3200
Website strataskinsciences.com

Stock Details

Ticker Symbol SSKN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001051514
CUSIP Number 86272A206
ISIN Number US86272A2069
Employer ID 13-3986004
SIC Code 3841

Key Executives

Name Position
Dr. Dolev Rafaeli Ph.D. President, Chief Executive Officer and Vice-Chairman
Shmuel Gov Chief Operating Officer
John Gillings Vice President of Finance
Jay Sturm General Counsel and Corporate Secretary
Michael R. Stewart Independent Consultant

Latest SEC Filings

Date Type Title
Dec 18, 2024 EFFECT Notice of Effectiveness
Dec 11, 2024 8-K Current Report
Dec 5, 2024 S-3/A [Amend] Registration statement under Securities Act of 1933
Nov 22, 2024 S-3 Registration statement under Securities Act of 1933
Nov 14, 2024 SCHEDULE 13G/A Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Nov 12, 2024 8-K Current Report
Oct 30, 2024 8-K Current Report